Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

The user discusses their long struggle with hair loss, considering various treatments like hair transplants, hair systems, and natural methods such as micro-needling, vitamin supplements, and a healthy lifestyle. They express concerns about side effects from drugs like finasteride and ultimately lean towards using a hair system for better appearance and confidence.

Hair loss treatments like Dutasteride, RU58841, Finasteride, and Minoxidil are discussed, with skepticism about their effectiveness without photographic evidence. The conversation humorously critiques the reliance on anecdotal evidence for these treatments.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Question asked if stopping Latanoprost causes loss of gained hair.

The conversation is about seeking advice on the potential benefits of two different hair sprays for hair loss, with a list of ingredients provided for each. Specific treatments were not discussed.

The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.

The conversation humorously discusses various hair loss treatments and options, including Minoxidil, finasteride, RU58841, biotin, ketoconazole, saw palmetto, dutasteride, and nutrition. It also mentions hair extensions and hairstyling as methods to achieve desired hairstyles.

The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.

The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.

Pyrilutamide is discussed as a potential hair loss treatment, acting as an androgen receptor antagonist. The conversation questions if it can maintain hair long-term without using finasteride.

The conversation is about finding a reliable source to buy RU58841 for hair loss treatment, specifically in Brazil. A user offers to help privately.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

Hair loss treatments like finasteride, minoxidil, and RU58841 are becoming more known, but many remain unaware of their effectiveness. There is hope for future advancements despite skepticism and misconceptions about current treatments.

Kintor is launching pyrilutamide as a cosmetic for hair loss. Users discuss its potential, comparing it to Cosmerna.

Dr. Bloxham's new channel will discuss verteporfin and other future hair loss treatments. Users express interest and hope for the effectiveness of these treatments.

The conversation humorously discusses various unconventional and satirical hair loss treatments, including Minoxidil, RU58841, dutasteride, and microneedling. It also mentions bizarre suggestions like topical sharpie, spray paint, and Nutella.

Hair transplants and hair loss treatments like oral Fin and Min are discussed, with some humor about public figures' hair. Missing a single day of these treatments typically has little impact, but longer gaps can affect results.

The conversation discusses the potential of GT20029 to stop hair loss and possibly regrow hair, considering the body's regenerative abilities. No specific treatments were mentioned due to the original post being removed.

A new human trial using an FDA-approved treatment for wound healing called Verteporfin, which may potentially be able to reverse scarring and regrow hair in that area. The trial is only lasting one month so far.

A user is seeking suggestions for a custom hair lotion mix containing minoxidil, finasteride, caffeine, niacinamide, and biotin. Another user suggests adding tretinoin, topical valproate, and bimatoprost.

The conversation humorously discusses hair loss treatments, mentioning a regime of 1mg oral finasteride, 5% topical finasteride, and 1mg kryptonite. It also references the use of minoxidil for hair regrowth.

A 12-year-old diagnosed with alopecia shares their experience and current treatments, including Dermovate, an unnamed cream, and liquid iron. The community offers support and encouragement.

The conversation discusses new hair loss treatments, mentioning Breezula and a promising treatment called pyrilutamide.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

Latanoprost at 0.1% concentration is used to increase hair counts, often mixed with Minoxidil and Finasteride. Users report noticeable results in about 3 months.

The user is hesitant to use finasteride due to potential hormonal side effects and is waiting for the release of pyrilutamide, a new hair loss treatment. Other users suggest trying finasteride, warning about potential regret if hair loss progresses in the meantime.

Skepticism about hair loss research motivations, suggesting financial interests hinder finding a cure. Mentions treatments like minoxidil, finasteride, and dutasteride, but notes they are not cures.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.